Cixutumumab
- Generic Name
- Cixutumumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 947687-12-9
- Unique Ingredient Identifier
- 2285XW22DR
- Background
Cixutumumab has been used in trials studying the treatment of Lung Cancer, Malignant Neoplasm, Leukemia, Mast-Cell, Non-Small-Cell Lung Carcinoma, and Adenocarcinoma of the Prostate.
Cixutumumab is a highly specific recombinant human monoclonal antibody with high affinity for the insulin-like growth factor-I receptor (IGF-IR). IGF-IR is overexpressed in a variety of tumour types.
- Associated Conditions
- -
- Associated Therapies
- -
Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
- Conditions
- Metastatic Esophageal AdenocarcinomaMetastatic Esophageal Squamous Cell CarcinomaMetastatic Gastroesophageal Junction AdenocarcinomaRecurrent Esophageal AdenocarcinomaRecurrent Esophageal CarcinomaRecurrent Esophageal Squamous Cell CarcinomaRecurrent Gastroesophageal Junction AdenocarcinomaStage IV Esophageal Cancer AJCC v7
- Interventions
- Other: Laboratory Biomarker AnalysisBiological: CixutumumabOther: Pharmacological StudyDrug: Paclitaxel
- First Posted Date
- 2010-06-11
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 94
- Registration Number
- NCT01142388
- Locations
- 🇺🇸
Carle Cancer Institute Normal, Normal, Illinois, United States
🇺🇸Ottawa Regional Hospital and Healthcare Center, Ottawa, Illinois, United States
🇺🇸OSF Saint Francis Radiation Oncology at Pekin, Pekin, Illinois, United States
Cixutumumab and Temsirolimus in Treating Patients With Locally Advanced or Metastatic Cancer
- Conditions
- Malignant Neoplasm
- Interventions
- First Posted Date
- 2008-05-16
- Last Posted Date
- 2015-11-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 72
- Registration Number
- NCT00678769
- Locations
- 🇺🇸
Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸M D Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.